Historical Press Releases

2014

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development

Princeton, NJ – September 23, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma

Princeton, NJ – November 10, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board

Princeton, NJ – November 17, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer

Princeton, NJ – December 10, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Princeton, NJ – December 11, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Show 5102550100 per page